Seminar Invitation: Pitfalls for SMEs in protecting and claiming incentives for new developments

Presented by:

  • Joe Seisdedos (Wrays)Wrays
  • Bill Charlton (UHY Haines Norton)
  • Michael Oon (Swanson Reed)

Join Swanson Reed, UHY Haines Norton and Wrays for a practical workshop that will focus on the problems that every day companies face in protecting, and claiming incentives for their new products.

You will hear from three industry experts on a range of topics, including tax issues, R&D tax incentives and patent protection.

On conclusion of the presentation, participants will have an opportunity to ask the panel any specific questions in a friendly and constructive forum.

 

Time Presentation Presenter
7:00am – 7:30am: Session 1: Protecting Intellectual Property (IP) Joe Seisdedos
7:30am – 8:00am: Session 2: IP & Relevant Tax Considerations Bill Charlton
8:00am – 8:30am: Session 3: R&D Tax Incentives Michael Oon
8:30am – 9:00am: Session 4: Panel Q&A and Networking Opportunity

 

Joe Seisdedos Bill Charlton Michael Oon
Joe_seisdedos Bill-Charlton Michael-Oon
 View Joe’s bio  View Bill’s bio  View Michael’s bio

Brisbane R&D Tax Seminar:


View Larger Map

Wednesday, 18th June 2014
7am – 9am
Swanson Reed Boardroom
Level 11, 42-60 Albert St
Brisbane, 4000

Cost: Free!
Register Before:
 Friday 13th June

Register your interest

Full attendance at this workshop will yield 2 CPE hours towards the Tax Practitioners Board’s (TPB) CPE requirements.

Contact Amy Nolan for more information:

Ph: 07 3221 1499
Mob: 0435 713 493

Are you Eligible to claim R&D? Take our R&D Eligibility Survey and find out.

Latest News

CBA Settlement of Disputed Claims for Software R&D Activities

CBA have announced to the ASX on 18 March that they have entered into a settlement in respect of a tax dispute re: the eligibility of claims for software development R&D activities. Below is an extract from the ASX announcement: Commonwealth Bank of Australia has agreed to withdraw from all current proceedings with the ATO and Innovation and Science Australia (ISA) before the AAT in respect of the eligibility of R&D claims that were made for the years ended 30 […]

Australia’s Attractiveness for Clinical Trials

To bring a new drug to market, an average of 12 years and $1.7 billion (US) in R&D spending is required. Yet only 1 in 5,000 drugs that begin preclinical testing make it to the market. This has led to a disproportionate number of drugs being developed for rare diseases (affecting less than 200,000 in the US at any given time) due to a 25.3% success rate versus 3.4% for oncology. Many argue this is unsustainable and there is pressure […]

Email this job

[recaptcha]